Orchid Pharma Limited (ORCHPHARMA.NS)
INR 719.7
(1.92%)
INR 719.7
(1.92%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 921.66 Million INR | 98.99% |
| 2022 | 463.18 Million INR | 2473.84% |
| 2021 | -19.51 Million INR | 98.33% |
| 2020 | -1.16 Billion INR | 11.09% |
| 2019 | -1.31 Billion INR | -288.84% |
| 2018 | 694.07 Million INR | 119.68% |
| 2017 | -3.52 Billion INR | 28.08% |
| 2016 | -4.9 Billion INR | -75.73% |
| 2015 | -2.79 Billion INR | -112.9% |
| 2014 | -1.31 Billion INR | 64.76% |
| 2013 | -3.72 Billion INR | -35.1% |
| 2012 | -2.75 Billion INR | -382.5% |
| 2011 | 974.78 Million INR | -37.59% |
| 2010 | 1.56 Billion INR | -53.96% |
| 2009 | 3.39 Billion INR | 792.5% |
| 2008 | -489.89 Million INR | -127.94% |
| 2007 | 1.75 Billion INR | 123.22% |
| 2006 | 785.48 Million INR | 37.08% |
| 2005 | 573 Million INR | 159.37% |
| 2004 | 220.92 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 293.5 Million INR | -12.46% |
| 2023 FY | 921.66 Million INR | 98.99% |
| 2023 Q1 | 94.04 Million INR | -84.1% |
| 2023 Q2 | 198.03 Million INR | 110.57% |
| 2023 Q3 | 294.31 Million INR | 48.62% |
| 2023 Q4 | 335.26 Million INR | 13.92% |
| 2022 FY | 463.18 Million INR | 2473.84% |
| 2022 Q4 | 591.39 Million INR | 679.5% |
| 2022 Q1 | -150.13 Million INR | -127.95% |
| 2022 Q2 | -53.94 Million INR | 64.07% |
| 2022 Q3 | 75.86 Million INR | 240.63% |
| 2021 Q4 | -65.86 Million INR | 52.49% |
| 2021 Q1 | -309.03 Million INR | -24.98% |
| 2021 FY | -19.51 Million INR | 98.33% |
| 2021 Q2 | 494.02 Million INR | 259.86% |
| 2021 Q3 | -138.63 Million INR | -128.06% |
| 2020 FY | -1.16 Billion INR | 11.09% |
| 2020 Q4 | -247.26 Million INR | 44.71% |
| 2020 Q3 | -447.24 Million INR | -83.17% |
| 2020 Q2 | -244.16 Million INR | -7.74% |
| 2020 Q1 | -226.62 Million INR | 41.68% |
| 2019 Q1 | -384.46 Million INR | 0.0% |
| 2019 FY | -1.31 Billion INR | -288.84% |
| 2019 Q4 | -388.59 Million INR | -40.32% |
| 2019 Q2 | -260.81 Million INR | 32.16% |
| 2019 Q3 | -276.92 Million INR | -6.18% |
| 2018 Q2 | -231.25 Million INR | 0.0% |
| 2018 FY | 694.07 Million INR | 119.68% |
| 2017 Q2 | -703.4 Million INR | 0.0% |
| 2017 FY | -3.52 Billion INR | 28.08% |
| 2016 FY | -4.9 Billion INR | -75.73% |
| 2015 FY | -2.79 Billion INR | -112.9% |
| 2015 Q1 | -475.62 Million INR | 0.0% |
| 2014 FY | -1.31 Billion INR | 64.76% |
| 2013 Q2 | -2 Billion INR | 0.0% |
| 2013 FY | -3.72 Billion INR | -35.1% |
| 2012 Q4 | -1.32 Billion INR | 0.0% |
| 2012 Q2 | -199.46 Million INR | 0.0% |
| 2012 FY | -2.75 Billion INR | -382.5% |
| 2011 Q4 | 205.51 Million INR | 0.0% |
| 2011 FY | 974.78 Million INR | -37.59% |
| 2010 FY | 1.56 Billion INR | -53.96% |
| 2009 FY | 3.39 Billion INR | 792.5% |
| 2008 FY | -489.89 Million INR | -127.94% |
| 2007 FY | 1.75 Billion INR | 123.22% |
| 2006 FY | 785.48 Million INR | 37.08% |
| 2005 FY | 573 Million INR | 159.37% |
| 2004 FY | 220.92 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 85.034% |
| Hester Biosciences Limited | 188.89 Million INR | -387.937% |
| Aarti Drugs Limited | 1.71 Billion INR | 46.233% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 57.508% |
| Albert David Limited | 754.2 Million INR | -22.204% |
| Alembic Limited | 2.68 Billion INR | 65.689% |
| Alkem Laboratories Limited | 17.95 Billion INR | 94.868% |
| Bafna Pharmaceuticals Limited | 73.47 Million INR | -1154.324% |
| Bajaj HealthCare Limited | -837.93 Million INR | 209.993% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -12895.84% |
| Brooks Laboratories Limited | -195.91 Million INR | 570.432% |
| Eris Lifesciences Limited | 3.91 Billion INR | 76.487% |
| FDC Limited | 3.05 Billion INR | 69.804% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 80.427% |
| Gufic Biosciences Limited | 861.35 Million INR | -7.002% |
| Hikal Limited | 696 Million INR | -32.423% |
| Ind-Swift Limited | 142.31 Million INR | -547.632% |
| Innova Captab Limited | 943.45 Million INR | 2.309% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 31.439% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -310.304% |
| Jubilant Pharmova Limited | 771 Million INR | -19.542% |
| Lincoln Pharmaceuticals Limited | 933.04 Million INR | 1.22% |
| Lupin Limited | 19.14 Billion INR | 95.186% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 1115.978% |
| Medico Remedies Limited | 82.9 Million INR | -1011.659% |
| Morepen Laboratories Limited | 961.59 Million INR | 4.153% |
| Nectar Lifesciences Limited | 49.95 Million INR | -1745.175% |
| Procter & Gamble Health Limited | 2 Billion INR | 54.141% |
| RPG Life Sciences Limited | 876.6 Million INR | -5.141% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -531.217% |
| Sigachi Industries Limited | 571.8 Million INR | -61.186% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 116.244% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 69.307% |
| Themis Medicare Limited | 435.23 Million INR | -111.761% |
| Unichem Laboratories Limited | -704.74 Million INR | 230.78% |
| Vaishali Pharma Limited | 7.18 Million INR | -12720.49% |
| Wanbury Limited | 559.56 Million INR | -64.712% |
| Windlas Biotech Limited | 581.87 Million INR | -58.397% |
| ZIM Laboratories Limited | 172.46 Million INR | -434.41% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 78.106% |
| Ipca Laboratories Limited | 5.47 Billion INR | 83.161% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.038% |
| Venus Remedies Limited | 284.9 Million INR | -223.496% |
| Sakar Healthcare Limited | 116.7 Million INR | -689.712% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 97.095% |
| Divi's Laboratories Limited | 16 Billion INR | 94.24% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 42.934% |
| Mankind Pharma Limited | 19.12 Billion INR | 95.182% |
| Sequent Scientific Limited | -358.69 Million INR | 356.953% |
| Laurus Labs Limited | 1.6 Billion INR | 42.593% |
| Neuland Laboratories Limited | 3 Billion INR | 69.286% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 83.322% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 106.138% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 97.612% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -104.939% |
| Wockhardt Limited | -4.63 Billion INR | 119.906% |
| Bal Pharma Limited | 73.92 Million INR | -1146.807% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 98.345% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -22.149% |
| Par Drugs and Chemicals Limited | 145.01 Million INR | -535.587% |
| Caplin Point Laboratories Limited | 4.57 Billion INR | 79.836% |
| Shilpa Medicare Limited | 318.74 Million INR | -189.157% |
| Valiant Laboratories Limited | 3.19 Million INR | -28738.079% |
| Ajanta Pharma Limited | 8.16 Billion INR | 88.707% |
| Aarey Drugs & Pharmaceuticals Limited | 46.83 Million INR | -1867.828% |
| Granules India Limited | 4.05 Billion INR | 77.26% |
| Medicamen Biotech Limited | 109.31 Million INR | -743.166% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -264.09% |
| Piramal Enterprises Limited | -16.83 Billion INR | 105.475% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 94.436% |
| NATCO Pharma Limited | 13.88 Billion INR | 93.361% |
| Suven Life Sciences Limited | -1.05 Billion INR | 187.714% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 567.177% |
| Strides Pharma Science Limited | -706.14 Million INR | 230.522% |
| Indoco Remedies Limited | 984.6 Million INR | 6.392% |
| Alpa Laboratories Limited | 167.76 Million INR | -449.379% |
| Lasa Supergenerics Limited | -217.3 Million INR | 524.132% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 123.802% |